Case series:dPD-1 hCD19CART

2 trials

Sponsors

Xinjiang Uygur Autonomous Region people's Hospital, Yantai Yuhuangding Hospital

Conditions

Refractory Aggressive Non-Hodgkin Lymphoma (NHL)Refractory/Relapsed lymphoma

Phase 1

dPD-1 hCD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed lymphoma

Active, not recruitingChiCTR1900025179

Xinjiang Uygur Autonomous Region people's HospitalRefractory/Relapsed lymphoma

Start: 2019-01-01Updated: 2019-08-27

dPD-1 hCD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non-Hodgkin's lymphoma

Active, not recruitingChiCTR1900025181

Yantai Yuhuangding HospitalRefractory Aggressive Non-Hodgkin Lymphoma (NHL)

Start: 2019-01-01Updated: 2019-08-27